Respivert Limited

Janssen Pharmaceutica Nv

Alex Herman Copmans

Stuart Thomas Onions

Kazuhiro Ito

John King-Underwood

Catherine Elisabeth Charron

Alistair Ian Longshaw

Rudy Laurent Maria Broeckx

Walter Filliers

Rudy Broeckx

Jérôme Emile Georges Guillemont

David Michel Adrien Taddei

Jozef Peeters

Alfred Elisabeth Stappers

Roger Petrus Gerebern Vandecruys

Alun John Smith

Paul Stoffels

Paul Theodoor Agnes Stevens

Marc Gaston Venet

Alfons G De Knaep

Albert Louis Willemsens

Anna Maria Vandendriessche

Walter Louis Verstappen

Roger Petrus Vandecruys

Paul Theodoor Stevens

Carina Leys

Walter Ferdinand Maria Filliers

Patrick Hubert J Nieste

Wouter Louis J Couck

Joannes Petrus Van Dun

Albert Louis Anna Willemsens

Jérôme Albert Joseph Hoet

Filip Marcel Vanhoutte

Jerome Albert Hoet

Wouter Louis Couck

Filip Marcel C Vanhoutte

There is provided a compound of formula (I) which is an inhibitor of the family of p38 mitogen-activated protein kinase enzymes, and to its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.

1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-i-yl) ureas as P38 mapkinase inhibitors

1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-I-yl) ureas as P38 mapkinase inhibitors

The present invention relates inter alia to a compound of formula (I) and to compositions comprising the same and to the use of the compounds and to compositions of the compounds in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making the said compounds. 

2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1H-pyrazolo[3,4-D]pyrimidin-1-yl)methyl)-3-(2-(trifluoromethyl)benzyl) quinazolin-4(3H)-one derivatives and their use as phosphoinositide 3-kinase inhibitors

There is provided inter alia 6-(2-((4-amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl) methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-N,N-bis(2-methoxyethyl)hex-5-ynamide in the form of a solid crystalline hydrate and in solid crystalline anhydrous form. There are also provided dry powder pharmaceutical compositions for inhalation containing such solid crystalline forms.

Crystalline 6-(2-((4-amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-D]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-0X0-3,4-dihydroquinazolin-5-yl)-N,N-bis(2-methoxyethyl)hex-5-ynamide

The present invention relates inter alia to a compound of formula (I) and to compositions comprising the same and to the use of the compounds and to compositions of the compounds in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making the said compounds.

Phosphoinositide 3-kinase inhibitors

There is provided a compound of formula (I) which is an inhibitor of the family of p38 mitogen-activated protein kinase enzymes, and to its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD. 

1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as p38 MAP kinase inhibitors

The present invention relates to a resolution process of (&#xb1;)-methyl phenyl[4-[4-[[[4'-(trifluoromethyl)-2-biphenylyl]carbonyl]amino]phenyl]-1-piperidinyl]acetate to isolate the MTP (microsomal triglyceride transfer protein) inhibitor methyl (2S)-phenyl[4-[4-[[[4&#x2032;-(trifluoromethyl)-2-biphenylyl]carbonyl]amino]phenyl]-1-piperidinyl]acetate and an epimerisation procedure for racemizing methyl (2R)-phenyl[4-[4-[[[4&#x2032;-(trifluoromethyl)-2-biphenylyl]carbonyl]amino]phenyl]-1-piperidinyl]acetate.

Resolution of (&#xb1;)-methyl phenyl[4-[4-[[[4'(trifluoromethyl)-2-biphenylyl]carbonyl]amino]Phenyl]-1-piperidinyl]acetate

The present invention relates to a pharmaceutical composition comprising as active ingredient the hydrochloric acid salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile and to processes for their preparation.

Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile

Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile

A process for preparing (+)-6-�(4-chlorophenyl)(1H- 1,2,4-triazol-1-yl)methyl!-1-methyl-1H-benzotriazole comprising the resolution of (.+-.)-6-!(4-chlorophenyl)-hydrazinomethyl)-1-methyl-1H-benzotriazole and converting the appropriate enantiomerically pure hydrazine intermediate into (+)-6-�(4-chlorophenyl)(H- 1,2,4-triazol-1-yl)methyl!-1-methyl-1H-benzotriazole.

Process for preparing enantiomerically pure 6-{4-chlorophenyl) (1

Process for preparing enantiomerically pure 6-[(4-chlorophenyl)

Growing community of inventors

Lille, Belgium

Alex Herman Copmans